1190 Evidence-Based Medicine [ 1 5 4 # 5 C H E S T N O V E M B E R 2 0 1 8 ] 89. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363(17):1608-1620. 90. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155-1166. 91. Heneghan CJ, Garcia-Alamino JM, Spencer EA, et al. Self- monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016;7:CD003839. 92. Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial brillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Paci c Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155-3179. 93. Douketis JD, Hasselblad V, Ortel TL. Bridging anticoagulation in patients with atrial brillation. N Engl J Med. 2016;374(1): 93-94. 94. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial brillation. N Engl J Med. 2015;373(9):823-833. 95. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial brillation who are at risk for falls. Arch Intern Med. 1999;159(7):677-685. 96. Pastori D, Lip GYH, Farcomeni A, et al. Incidence of bleeding in patients with atrial brillation and advanced liver brosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Int J Cardiol. 2018;264:58-63. 97. Kuo L, Chao TF, Liu CJ, et al. 